Background: In the recent COVID19 pandemic, patients with hematological malignancies were considered high risk for severe disease. Limited data is available regarding course of COVID19 infection in this subgroup. Case Presentation: We describe a case of 32-year‐old man with paroxysmal nocturnal hemoglobinuria (PNH) undergoing treatment with ravulizumab (Ultomiris) who presented with COVID19 infection. He experienced only mild symptoms and had a rapid recovery from COVID19 infection. Conclusion: This case may demonstrate the beneficial effects of ravulizumab on complement mediated inflammatory damage linked with COVID19 infection especially in PNH patients.

No abstract